Effect of Formoterol in treatment of covid19

Phase 3

Completed

• Conditions: Condition 1: corona virus or COVID-19. Condition 2: COVID 19 ,virus not identified.; COVID-19, virus identified; COVID-19, virus not identified; U07.1; U07.2

• Registration Number: IRCT20170210032478N3
• Lead Sponsor: ational Research Institute of Tuberculosis and Lung Diseases

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 22 February 2021

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

(COVID-19) with according to the clinical manifestations confirmed with CBC, CRP, and Chest radiography or other lab tests
Patients who voluntarily sign our consent form.

Exclusion Criteria

Pregnancy
Comorbidity
Saturation less than 93%
The presence of symptoms for more than 7 days
History of formoterol intolerance
cardiac diseases, such as heart failure or arrhythmia
Recent history of using inhaled corticosteroids, bronchodilators, and ACE inhibitors
Asthma or COPD
Heavy Smoker

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
evel of Improvement. Timepoint: the 5th and 10th days. Method of measurement: clinical evaluation, observation, physical examination, and call interview for follow up.

Secondary Outcome Measures

Name	Time	Method
Total time to improvement. Timepoint: up to 30 days follow-up. Method of measurement: observation.